TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inhibikase Therapeutics ( (IKT) ) has provided an announcement.
On November 20, 2025, Inhibikase Therapeutics announced plans to advance IKT-001 to a global pivotal Phase 3 clinical study for Pulmonary Arterial Hypertension, expected to begin in the first quarter of 2026. The study, named IMPROVE-PAH, will be conducted in two parts, with Part A focusing on pulmonary vascular resistance and Part B on the 6-minute walk distance. The company believes this adaptive study design offers significant advantages, such as a dose-titration phase and uninterrupted enrollment. Additionally, Inhibikase terminated its ATM Prospectus but maintained the Sales Agreement with Jefferies LLC, indicating a strategic shift in its financial operations.
The most recent analyst rating on (IKT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inhibikase Therapeutics stock, see the IKT Stock Forecast page.
Spark’s Take on IKT Stock
According to Spark, TipRanks’ AI Analyst, IKT is a Neutral.
Inhibikase Therapeutics’ stock score is primarily impacted by its poor financial performance, marked by declining revenues and persistent losses. Technical analysis paints a mixed picture, with short-term indicators slightly positive but overshadowed by longer-term negative trends. Valuation metrics indicate caution due to a negative P/E ratio. The recent leadership change provides a potential positive catalyst for future performance, but its impact remains to be seen.
To see Spark’s full report on IKT stock, click here.
More about Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing treatments for diseases such as Pulmonary Arterial Hypertension (PAH). The company is advancing its primary product, IKT-001, which is a pro-drug designed to improve the efficacy and tolerability of imatinib, a tyrosine kinase inhibitor, for treating PAH.
Average Trading Volume: 113,954
Technical Sentiment Signal: Sell
Current Market Cap: $117.3M
For an in-depth examination of IKT stock, go to TipRanks’ Overview page.